Literature DB >> 30039778

Response to the Canadian Agency for Drugs and Technologies in Health and Institut national d'excellence en santé et en services sociaux decision regarding nusinersen for Spinal Muscular Atrophy.

Craig Campbell1, Kathy Selby2, Hugh McMillan3, Jiri Vajsar4, Lawrence Korngut5, Bernard Brais6, Alex MacKenzie7, Maryam Oskoui8.   

Abstract

Entities:  

Keywords:  Nusinersen; Spinal muscular atrophy

Year:  2018        PMID: 30039778     DOI: 10.1017/cjn.2018.59

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


× No keyword cloud information.
  2 in total

Review 1.  Recent advances in understanding congenital myopathies.

Authors:  Gianina Ravenscroft; Robert J Bryson-Richardson; Kristen J Nowak; Nigel G Laing
Journal:  F1000Res       Date:  2018-12-11

2.  Emergency contraception subsidy in Canada: a comparative policy analysis.

Authors:  Sabrina C Lee; Wendy V Norman
Journal:  BMC Health Serv Res       Date:  2022-09-01       Impact factor: 2.908

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.